Alkem Delivers Strong Quarter With Domestic Recovery
As Company’s Subsidiary Receives Marketing Approval For Two Biosimilars In India
Executive Summary
India’s Alkem has delivered a strong quarter with a boost in its domestic business on the back of “strong volume-led growth in the acute therapies and faster than market growth in chronic therapies.” However, the company saw a slight YoY decline in the US.
You may also be interested in...
Alkem’s US Business Doubles And Continues To Grow
India’s Alkem Laboratories has reported double-digit growth in its US business for financial year 2021, after seeing its US business double in four years. The company also saw recovery in its domestic business on the back of robust growth delivered by its generics business.
AAM Applauds HHS For Acknowledging Brand-Driven Cost Increases
The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”
Lupin Strikes Deal For Anti-TB Drug Pretomanid
Lupin and non-profit organization TB Alliance have entered into a partnership for a new therapy for highly drug-resistant tuberculosis, pretomanid, to be distributed in 140 countries and territories.